533
Views
38
CrossRef citations to date
0
Altmetric
Review Article

Effects of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials

Pages 8-14 | Received 10 Jun 2013, Accepted 10 Jun 2013, Published online: 27 Aug 2013
 

Abstract

Objective. We review four randomised, controlled trials investigating the efficacy of Ginkgo biloba extract EGb 761® in elderly patients with Alzheimer or vascular dementia with neuropsychiatric features. Methods. Patients with a total score of 9–23 in the Syndrom–Kurz test (SKT) cognitive test battery (cognitive domain) and with a composite score 6 and greater in the Neuropsychiatric Inventory (NPI; behavioural domain) were included. Three trials compared 2 × 120 mg/day or 1 × 240 mg/day EGb 761® to placebo while one used donepezil as an active control. The duration of randomised treatment was 22 or 24 weeks. Results. One thousand, two hundred and ninety-four patients were analysed for efficacy. Patients treated with EGb 761® showed improvements of cognitive performance and behavioural symptoms that were associated with advances in activities of daily living and a reduced burden to caregivers. Placebo-treated patients, on the other hand, showed only minimal improvements or signs of progression. In each placebo-controlled trial, EGb 761® was significantly superior in all mentioned domains (p < 0.01). In the actively controlled trial, EGb 761® and donezepil as well as a combination of both drugs had similar effects. Conclusions. The review supports the efficacy of EGb 761® in age-related dementia with neuropsychiatric features. The drug was safe and well-tolerated.

Acknowledgements

None.

Statement of interest

Prof. Dr. Ralf Ihl received grants/research support or was involved as consultant, speaker or in advisory boards or received authors honoraria within the last three years from APK, Austroplant, BDI, Beltz Test, BOD, Caritas Siegen, Double Helix Development, Eisai, Friedrichverlag, GE Healthcare, Hogrefe, IFE, Janssen, KDA, Landesinitiative Demenz Service NRW, LVR Düren, Lundbeck, Medical Tribune, Med. Komm., Novartis, Pfizer, Pfrimmer Nutritia, Pierrel, Schwabe, Thieme, Urban & Vogel, Westermayer.

Notes

1Manufacturer: Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany. EGb 761® is a registered trademark of Dr. Willmar Schwabe GmbH & Co. KG.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 526.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.